NCT07135128 is a Phase 1 clinical trial of 225Ac-FAPI-XT in Advanced Solid Tumor, sponsored by Xiaorong Sun.

Who is sponsoring NCT07135128?

NCT07135128 is sponsored by Xiaorong Sun.

What drugs are being tested in NCT07135128?

Interventions in NCT07135128: 225Ac-FAPI-XT.

What condition does NCT07135128 study?

NCT07135128 studies Advanced Solid Tumor.

Is NCT07135128 still recruiting?

NCT07135128 is currently recruiting now. Last updated 21 August 2025.

Last reviewed 2025-08-21 · How we verify

NCT07135128

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors

Recruiting now Phase 1 Last updated 21 August 2025

What this trial tests

Phase 1 trial testing 225Ac-FAPI-XT in Advanced Solid Tumor in 20 participants. Currently enrolling.

Timeline

14 October 2024

Primary endpoint
30 June 2026

1 December 2026

Quick facts

Lead sponsor	Xiaorong Sun
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	14 October 2024
Primary completion	30 June 2026
Estimated completion	1 December 2026
Sites	1 location across China

Drugs / interventions tested

225Ac-FAPI-XT — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Xiaorong Sun — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, single-arm clinical study to evaluate the safety, tolerability and preliminary efficacy of \[225Ac\]Ac-FAPI-XT injection in patients with FAP-positive advanced solid tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other Xiaorong Sun trials

Trials by the same sponsor.

NCT07135102 — A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patient · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07135128 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiaorong Sun
Last refreshed: 21 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07135128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing